Partially Hydrolyzed Guar Gum (PHGG)
Sunfiber
A low-viscosity, tasteless soluble fiber from the guar bean — a reliable bifidogenic prebiotic and an IBS/gut-regularity workhorse.
Evidence tier
Moderate
Research weight
Citations
9 verified / 9
Classification
Prebiotics & Fibers
❝
What the evidence says. Several controlled trials; effects real but modest or context-dependent.
What is Partially Hydrolyzed Guar Gum (PHGG)?
Partially Hydrolyzed Guar Gum (PHGG) (Sunfiber) is a prebiotic fiber used for prebiotic / bifidogenic: human trials and the pagoda rct show phgg increases bifidobacterium, faecalibacterium and ruminococcus and boosts colonic scfa (butyrate) production. NutriDex grades the human evidence as Moderate. Partially hydrolyzed guar gum (PHGG; the galactomannan of Cyamopsis tetragonoloba, enzymatically shortened to lower its viscosity and marketed as Sunfiber) is a 100% soluble, highly fermentable dietary fiber that dissolves clear and tasteless. Unlike native guar gum it does not gel or thicken, so it is well tolerated and used to fortify foods, beverages, and tube-feed formulas. The best human evidence is for gut function and the microbiome: randomized trials and a systematic review/meta-analysis show it normalizes stool form and increases defecation frequency, reduces bloating in IBS, and reliably acts as a prebiotic — raising Bifidobacterium, Faecalibacterium, and short-chain fatty acid (SCFA) production. Metabolic effects are more modest: pooled RCT data show small HbA1c reductions (and fasting-glucose lowering mainly in type 2 diabetes at higher doses), with weaker, less consistent weight and lipid signals.
Purported Benefits
✓Prebiotic / bifidogenic: human trials and the PAGODA RCT show PHGG increases Bifidobacterium, Faecalibacterium and Ruminococcus and boosts colonic SCFA (butyrate) production
✓IBS symptom relief: 6 g/day improved bloating and gas scores and normalized Bristol stool form versus placebo, with benefit in both diarrhea- and constipation-predominant patterns
✓Bowel regularity: a meta-analysis in healthy adults found PHGG significantly increased defecation frequency (SMD 0.58/day), and trials show faster colonic transit and reduced laxative use
✓Modest glycemic benefit: pooled RCTs show lower HbA1c, with fasting-glucose reductions concentrated in type 2 diabetes and higher doses (>15 g/day); blunts postprandial glucose/insulin
✓Satiety and dietary regulation: increases post-meal satiety and can reduce subsequent energy/snacking intake (basis of an EFSA-assessed satiety claim, though body-weight evidence is weaker)
✓Tube-feeding tolerance: low viscosity lets it mix into enteral formulas to reduce the incidence and severity of feeding-associated diarrhea
Evidence by outcome
The same supplement can be well-proven for one use and unproven for another — here is the human evidence graded outcome by outcome.
| Outcome | Evidence | Effect | Studies |
|---|---|---|---|
| Increases defecation frequency / bowel regularityMeta-analysis (SMD 0.58/day, I2=0) plus RCT showing faster transit; consistent in healthy and constipated adults. | Moderate | ↑ benefit · moderate | 2 |
| Reduces IBS symptoms (bloating/gas)One 12-week RCT (n=121) at 6 g/day improved bloating with benefit persisting post-treatment; single trial but well-conducted. | Moderate | ↑ benefit · moderate | 1 |
| Prebiotic: raises Bifidobacterium & SCFAPAGODA and other RCTs show bifidogenic/butyrate effects, though changes reversed after washout. | Moderate | ↑ benefit · moderate | 2 |
| Improves glycemic control (HbA1c)GRADE meta-analysis of 14 RCTs: HbA1c WMD -0.47; fasting glucose fell only in T2D at >15 g/day. | Moderate | ↑ benefit · small | 1 |
| Increases satiety / reduces energy intakeAcute crossover trial showed more satiety; EFSA did NOT substantiate satiety or body-weight claims as worded. | Preliminary | ↑ benefit · small | 1 |
| Body weight / blood pressureMeta-analysis found no significant effect on body mass or blood pressure. | Moderate | — no effect · negligible | 1 |
Dosing & Compounds
Typical Dose
Typical effective dose is about 5-7 g/day for bowel regularity, microbiome/prebiotic effects, and IBS (e.g. 6 g/day in IBS trials; 5 g up to 3x/day in the PAGODA microbiome trial). Higher doses (>15 g/day) are used in glycemic and weight studies. Taken as a tasteless powder dissolved in water or any drink, with no need for the large fluid bolus that viscous fibers require; start low (a few grams) and titrate up to limit gas.
Active Compounds
Safety & Cautions
Generally very well tolerated — because PHGG is low-viscosity and non-gelling it lacks the choking/esophageal-obstruction hazard that concentrated swelling fibers (native guar gum tablets, glucomannan/konjac) carry; the FDA's 1992 ban on guar gum in weight-loss tablets was specifically about that mechanical risk, not PHGG powders. As a fully fermentable fiber it is a FODMAP-type substrate, so transient gas, bloating, and flatulence are the main side effects, dose-dependent and usually mild; titrating up over days minimizes this. People prone to IBS gas, those with severe GI dysmotility, or anyone with a guar/legume allergy should be cautious. Like other soluble fibers, taking large amounts together with oral medications can slow or reduce drug absorption, so separate doses (take medicines ~1-2 hours apart). EFSA's ANS/FAF panels found no safety concern for guar-gum-derived fiber at food-additive levels. Educational only — always check with your doctor or pharmacist before combining Partially Hydrolyzed Guar Gum (PHGG) with any medicine.
Key Studies
Meta-analysis
Khalighi-Sigaroodi et al. 2023 (Diabetes Res Clin Pract)
✓ PubMed
GRADE-assessed meta-analysis of 14 RCTs found guar gum supplementation lowered HbA1c (WMD -0.47, 95% CI -0.75 to -0.18, p=0.001); fasting glucose fell only in type 2 diabetes and at doses >15 g/day, with no overall effect on body mass or blood pressure.
Systematic review & meta-analysis
Yasukawa et al. 2019 (J Funct Foods / systematic review)
✓ Full text
Systematic review and meta-analysis (15 trials, 7 studies, 325 healthy adults) found 5-7 g/day PHGG significantly increased fecal defecation frequency (SMD 0.58 times/day, 95% CI 0.43-0.74, I2=0, p<0.00001).
Regulatory assessment
EFSA NDA Panel 2010
✓ Source
EFSA scientific opinion assessed health claims for PHGG: found a cause-and-effect basis for reduction of post-prandial glycaemic responses, but did not substantiate claims for satiety, body weight, cholesterol, or triglycerides as worded.
Randomized clinical trial
Reider et al. 2020 (PAGODA trial, Nutrients)
✓ Full text
9-week trial in 20 healthy adults given up to 5 g PHGG 3x/day shifted the microbiota (bloom in Ruminococcus, Fusicatenibacter, Faecalibacterium, Bacteroides) and increased SCFA production, with effects reversing after washout.
Randomized controlled trial
Rao et al. 2021 (Long-term care RCT, J Nutr Health Aging)
✓ PubMed
Randomized single-blind placebo-controlled trial in long-term-care residents: PHGG significantly reduced laxative use vs control, though bowel-movement frequency itself did not differ significantly.
Randomized controlled trial
Niv et al. 2016 (United European Gastroenterol J)
✓ Full text
Randomized double-blind placebo-controlled trial in IBS (121 randomized): 6 g/day PHGG for 12 weeks significantly improved bloating and bloating+gas scores vs placebo, with benefit persisting 4 weeks after treatment.
Randomized controlled trial
Yoon et al. 2019 (Nutrients)
✓ Full text
Randomized double-blind placebo-controlled parallel trial: repeated PHGG consumption improved fecal characteristics and shifted gut microbiota, increasing beneficial bacteria vs placebo.
Randomized crossover trial
Rao 2015 (Br J Nutr)
✓ PubMed
Acute randomized study found PHGG intake increased post-meal perceivable satiety and reduced subsequent energy intake versus control.
Clinical trial
Polymeros et al. 2014 (Dig Dis Sci)
✓ PubMed
In adults with chronic constipation, PHGG significantly accelerated colonic transit time and increased complete spontaneous and spontaneous bowel movements (p<0.001) while improving symptoms.